Alaunos Therapeutics, Inc.
TCRT · Pharmaceutical Preparations · 24.4M shares · -80%/yr ↓ buyback · EDGAR filings ↗
Net buyback after stock comp: -$390K (gross $45K, SBC $435K)
Reference price $2.01 · est. market cap ~$49M — last insider sale, 2024-12-31 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D40Clinical/early-stage biotech — deep losses, micro-cap.
Strengths
- Liquidity — current ratio 2.4 (33rd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Cash burnNegative free cash flow (-3.0M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -83520.0%)
- Buying back stockNet buyback — share count -80%/yr over 3y
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
- Revenue declineRevenue -100.0% YoY
- New fund positionNotable fund(s) opened this quarter: CITADEL ADVISORS LLC
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-84500.0%
Net margin
-83520.0%
Return on equity
-194.0%
Return on assets
-140.8%
Revenue growth (QoQ)
-100.0%
Current ratio
2.4×
Free cash flow
-$3M
Tangible book value
$2M
Cash & investments
$1M
Cash runway
2q
Stock comp / revenue
15920.0%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-12 | Weis Holger | Grant | 7.8K | $2.26 |
| 2026-05-22 | Weis Holger | Grant | 3.7K | $2.37 |
| 2026-04-29 | Vieser Jaime | Grant | 6.5K | $2.59 |
| 2026-04-29 | Postma Robert W | Grant | 6.3K | $2.59 |
| 2026-04-29 | Jerman Michael Allen | Grant | 6.0K | $2.59 |
| 2026-01-12 | Jerman Michael Allen | Grant | 5.4K | $2.89 |
| 2026-01-12 | Postma Robert W | Grant | 5.6K | $2.89 |
| 2026-01-12 | Vieser Jaime | Grant | 5.8K | $2.89 |
| 2025-11-21 | Vieser Jaime | Grant | 5.3K | $3.16 |
| 2025-11-21 | Postma Robert W | Grant | 5.1K | $3.16 |
| 2025-11-21 | Jerman Michael Allen | Grant | 4.2K | $3.16 |
| 2025-08-18 | Groenewald Ferdinand | Grant | 11K | — |
| 2025-07-03 | Postma Robert W | Grant | 4.0K | — |
| 2025-07-03 | Vieser Jaime | Grant | 3.4K | — |
| 2025-04-13 | Postma Robert W | Grant | 21K | $2.92 |
| 2025-04-13 | Postma Robert W | Grant | 21K | $2.92 |
| 2025-04-13 | Vieser Jaime | Grant | 17K | — |
| 2024-12-31 | Vieser Jaime | Sell | 2.2K | $2.01 |
| 2024-12-31 | Vieser Jaime | Sell | 818 | $2.00 |
All non-derivative Form 4 activity (SEC), newest first.
Supply chain
Customers (0)
Suppliers (4)
- Bruker BioSpin
- Cantor Fitzgerald & Co.
- Precigen
- The University of Texas MD Anderson Cancer Center
Named in the 10-K; linked when we track them.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-26 | 2026-05-26 | 0001193125-26-238237 ↗ |
| 8-K | 2026-05-18 | 2026-05-18 | 0001193125-26-227921 ↗ |
| 10-Q | 2026-05-15 | 2026-03-31 | 0001193125-26-227272 ↗ |
| 10-K/A | 2026-04-30 | 2025-12-31 | 0001193125-26-197838 ↗ |
| 8-K | 2026-04-15 | 2026-04-09 | 0001193125-26-157126 ↗ |
| 10-K | 2026-03-31 | 2025-12-31 | 0001193125-26-134720 ↗ |
| 8-K | 2026-03-02 | 2026-03-02 | 0001193125-26-084084 ↗ |
| 8-K | 2026-01-08 | 2026-01-08 | 0001193125-26-007054 ↗ |
| 8-K | 2025-12-23 | 2025-12-17 | 0001193125-25-331147 ↗ |
| 10-Q | 2025-11-14 | 2025-09-30 | 0001193125-25-282988 ↗ |
| 8-K | 2025-08-20 | 2025-08-19 | 0000950170-25-110484 ↗ |
| 10-Q | 2025-08-14 | 2025-06-30 | 0000950170-25-108887 ↗ |